| pubmed-article:21421022 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21421022 | lifeskim:mentions | umls-concept:C0228398 | lld:lifeskim |
| pubmed-article:21421022 | lifeskim:mentions | umls-concept:C0205095 | lld:lifeskim |
| pubmed-article:21421022 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:21421022 | lifeskim:mentions | umls-concept:C0031937 | lld:lifeskim |
| pubmed-article:21421022 | lifeskim:mentions | umls-concept:C0070122 | lld:lifeskim |
| pubmed-article:21421022 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:21421022 | lifeskim:mentions | umls-concept:C0086597 | lld:lifeskim |
| pubmed-article:21421022 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:21421022 | lifeskim:mentions | umls-concept:C0205250 | lld:lifeskim |
| pubmed-article:21421022 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:21421022 | pubmed:dateCreated | 2011-4-25 | lld:pubmed |
| pubmed-article:21421022 | pubmed:abstractText | The ?-adrenergic blocker and 5-HT(1A) receptor antagonist pindolol has been combined with selective serotonin reuptake inhibitors (SSRIs) in patients with depressive and anxiety disorders to shorten the onset of the clinical action and/or increase the proportion of responders. The results of a previous study have shown that pindolol potentiates the panicolytic effect of paroxetine in rats submitted to the elevated T-maze (ETM). Since reported evidence has implicated the 5-HT(1A) receptors of the dorsal periaqueductal gray matter (DPAG) in the panicolytic effect of antidepressants, rats treated with pindolol (5.0mg/kg, i.p.) and paroxetine (1.5mg/kg, i.p.) received a previous intra-DPAG injection of the selective 5-HT(1A) antagonist, WAY-100635 (0.4 ?g) and were submitted to the ETM. Pretreatment with WAY-100635 reversed the increase in escape latency, a panicolytic effect, determined by the pindolol-paroxetine combination. These results implicate the 5-HT(1A) receptors of the DPAG in the panicolytic effect of the pindolol-paroxetine combination administered systemically. They also give further preclinical support for the use of this drug combination in the treatment of panic disorder. | lld:pubmed |
| pubmed-article:21421022 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21421022 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21421022 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21421022 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21421022 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21421022 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21421022 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21421022 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21421022 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21421022 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21421022 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21421022 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21421022 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21421022 | pubmed:month | May | lld:pubmed |
| pubmed-article:21421022 | pubmed:issn | 1872-7972 | lld:pubmed |
| pubmed-article:21421022 | pubmed:author | pubmed-author:ZangrossiHéli... | lld:pubmed |
| pubmed-article:21421022 | pubmed:author | pubmed-author:AudiElisabeth... | lld:pubmed |
| pubmed-article:21421022 | pubmed:author | pubmed-author:GraeffFrederi... | lld:pubmed |
| pubmed-article:21421022 | pubmed:author | pubmed-author:SelaVânia... | lld:pubmed |
| pubmed-article:21421022 | pubmed:author | pubmed-author:BiesdorfCarla... | lld:pubmed |
| pubmed-article:21421022 | pubmed:author | pubmed-author:RamosDiego... | lld:pubmed |
| pubmed-article:21421022 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:21421022 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21421022 | pubmed:day | 9 | lld:pubmed |
| pubmed-article:21421022 | pubmed:volume | 495 | lld:pubmed |
| pubmed-article:21421022 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21421022 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21421022 | pubmed:pagination | 63-6 | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:meshHeading | pubmed-meshheading:21421022... | lld:pubmed |
| pubmed-article:21421022 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21421022 | pubmed:articleTitle | Serotonin-1A receptors in the dorsal periaqueductal gray matter mediate the panicolytic-like effect of pindolol and paroxetine combination in the elevated T-maze. | lld:pubmed |
| pubmed-article:21421022 | pubmed:affiliation | Department of Pharmacology and Therapeutic, State University of Maringá, Av. Colombo, 5790 - Jardim Universitário, CEP: 87020900 Maringá, PR, Brazil. | lld:pubmed |
| pubmed-article:21421022 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21421022 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:24473 | entrezgene:pubmed | pubmed-article:21421022 | lld:entrezgene |
